92% Success Rate
Average Monthly Weight Loss: 12-16 LBS
What is Semaglutide/Tirzepatide?
Semaglutide/Tirzepatide an incretin mimetic; specifically, semaglutide is a GLP-1 receptor agonist with 94% sequence homology to human GLP-1. Semaglutide binds and initiates the GLP-1 receptor. GLP-1 is an important, gut-derived, glucose homeostasis regulator that is released after the oral ingestion of carbohydrates or fats. In patients with Type 2 diabetes, GLP-1 concentrations are decreased in response to an oral glucose load. GLP-1 enhances insulin secretion; it increases glucose-dependent insulin synthesis and in vivo secretion of insulin from pancreatic beta cells in the presence of elevated glucose. In addition to increases in insulin secretion and synthesis, GLP-1 suppresses Glc secretion, slows gastric emptying, reduces food intake, and promotes beta-cell proliferation. The principal mechanism of protraction resulting in the long half-life of semaglutide is albumin binding, which results in decreased renal clearance and protection from metabolic degradation; semaglutide is stabilized against degradation by the DPP-4 enzyme. Semaglutide reduces blood glucose through a mechanism where it stimulates insulin secretion and lowers Glc secretion, both in a glucose-dependent manner. Therefore, when blood glucose is high, insulin secretion is stimulated and Glc secretion is inhibited. The mechanism of blood glucose lowering also involves a minor delay in gastric emptying in the early postprandial phase.
Semaglutide/Tirzepatide Injection works by simulating hormones that affect areas of the brain involved in regulating appetite and food intake. This can help you eat less and lead to weight loss.
– Weight Loss
– May improve Blood Pressure
– May improve cholesterol
– Improves Blood Sugar
**Must have a BMI OF 27 OR GREATER**